| Literature DB >> 28892148 |
G Gordo1,2,3, J Tenorio1,2, P Arias1,2, F Santos-Simarro1,4, S García-Miñaur1,4, J C Moreno1,2, J Nevado1,5, E Vallespin1,5, L Rodriguez-Laguna1,3, R de Mena1,5, I Dapia1,2, M Palomares-Bralo1,5, Á Del Pozo1,6, K Ibañez1,6, J C Silla1,6, E Barroso1,2, V L Ruiz-Pérez1,7, V Martinez-Glez1,3,4, P Lapunzina1,2,4.
Abstract
Smith-Kingsmore syndrome (SKS) OMIM #616638, also known as MINDS syndrome (ORPHA 457485), is a rare autosomal dominant disorder reported so far in 23 patients. SKS is characterized by intellectual disability, macrocephaly/hemi/megalencephaly, and seizures. It is also associated with a pattern of facial dysmorphology and other non-neurological features. Germline or mosaic mutations of the mTOR gene have been detected in all patients. The mTOR gene is a key regulator of cell growth, cell proliferation, protein synthesis and synaptic plasticity, and the mTOR pathway (PI3K-AKT-mTOR) is highly regulated and critical for cell survival and apoptosis. Mutations in different genes in this pathway result in known rare diseases implicated in hemi/megalencephaly with epilepsy, as the tuberous sclerosis complex caused by mutations in TSC1 and TSC2, or the PIK3CA-related overgrowth spectrum (PROS). We here present 4 new cases of SKS, review all clinical and molecular aspects of this disorder, as well as some characteristics of the patients with only brain mTOR somatic mutations.Entities:
Keywords: MINDS syndrome; Smith-Kingsmore syndrome; constitutive mosaicism; germline mosaicism; gonadal mosaicism; mTOR; macrocephaly; megalencephaly; somatic mosaicism
Mesh:
Substances:
Year: 2018 PMID: 28892148 DOI: 10.1111/cge.13135
Source DB: PubMed Journal: Clin Genet ISSN: 0009-9163 Impact factor: 4.438